5.4.2 Supportive therapies
Supportive therapies may be necessary for CAYA with acute leukaemia, particularly due to the risk of cardiotoxicity and secondarily to using anthracyclines.
Late complications specifically related to CAYA acute leukaemia may include:
- deficits in neurocognitive functioning, particularly with CNS-directed therapy
- impaired cardiac function due to anthracycline chemotherapy
- neuropathy
- risk of obesity and metabolic syndrome, particularly in those patients treated with cranial
All patients who have been treated for leukaemia should participate in a survivorship program for at least three years after completing treatment.
Increased surveillance and monitoring are necessary for those who have undergone a transplant due to the increased toxicities of therapy, particularly during conditioning and graft-versus-host disease.
For more information on supportive care and needs that may arise for different population groups, see Appendices A, B and C.